R1626: Phase IIa data

In a U.S. Phase IIa trial in 104 treatment-naïve patients with HCV genotype 1 infection, HCV was undetectable (HCV-RNA <15 IU/mL) at 48 weeks in 84% of patients receiving 1,500 mg R1626 twice daily pl...